NCT00852696

Over Active Bladder Patients Having Sling Surgery

A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Cleveland Clinic Florida · Academic / Other
• Sex: Female
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether treatment with anti-muscarinic medications following sub-urethral sling procedures improves overall subjective and objective outcomes in women with mixed incontinence with primary stress symptoms.

Detailed description

Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will take orally once daily for 9 weeks.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Solifenacin	Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
OTHER	Placebo	Take orally once daily for 9 weeks.

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-07-01
• Completion: 2010-02-01
• First posted: 2009-02-27
• Last updated: 2022-07-01
• Results posted: 2022-07-01

Locations

1 site across 1 country: United States